دورية أكاديمية

Blastic plasmacytoid dendritic cell neoplasm: First retrospective study in the Czech Republic.

التفاصيل البيبلوغرافية
العنوان: Blastic plasmacytoid dendritic cell neoplasm: First retrospective study in the Czech Republic.
المؤلفون: CERNAN, M., SZOTKOWSKI, T., HISEMOVA, M., CETKOVSKY, P., SRAMKOVA, L., STARY, J., RACIL, Z., MAYER, J., SRAMEK, J., JINDRA, P., VISEK, B., ZAK, P., NOVAK, J., KOZAK, T., FURST, T., PAPAJIK, T.
المصدر: Neoplasma; 2020, Vol. 67 Issue 3, p650-659, 10p, 4 Charts, 1 Graph
مستخلص: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with aggressive behavior and poor prognosis. We present the first retrospective analysis mapping its incidence and therapeutic outcomes in patients diagnosed and treated from 2000 to 2017 in the Czech Republic. The cohort comprised 14 patients (10 males, 4 females) with a median age at diagnosis of 39 years (range, 5-68 years). Initially, skin involvement was noted in 10 (71%) patients and bone marrow infiltration was present in 9 (64%). The first complete remission was achieved in 6/14 (43%) patients after acute lymphoblastic leukemia/lymphoma induction therapy and in 3/14 (21%) patients after acute myeloid leukemia regimen. Nine patients underwent allogeneic hematopoietic cell transplantation, with two patients achieving the first complete remission only after allogeneic transplantation. Patients undergoing allogeneic hematopoietic cell transplantation had longer overall survival than those treated without transplantation (the median survival over the period 16.4 vs. 8.1 months). Relapse of the disease was a significant predictor of mortality (p=0.05). Over the study period, patients’ survival ranged from 3.3 to 44.2 months, with a median overall survival of 13 months. Our results revealed an effectivity of allogeneic hematopoietic cell transplantation on complete remission achievement in refractory/relapsed disease. The study aimed to present the actual data from the Czech Republic and thus contribute to a global understanding of BPDCN. [ABSTRACT FROM AUTHOR]
Copyright of Neoplasma is the property of AEPress s.r.o. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00282685
DOI:10.4149/neo_2020_190507N407